Fintel reports that on July 29, 2025, William Blair downgraded their outlook for Neogen (NasdaqGS:NEOG) from Outperform to ...

Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of ...

Tomorrow, July 31, 2025, Figma plans to begin trading on the New York Stock Exchange under the ticker symbol "FIG." ...

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing ...

Data analytics firm Verisk said on Wednesday it will buy AccuLynx, which makes software for roofing contractors, for $2.35 ...

Discover SiteOne's Q2 2025 earnings insights: solid performance with improved margins, market share gains, and strategic acquisitions.

But while many analysts presented a bullish case for the company's turnaround, not all investors are sold on Niccol and his ...

Gain insights into Watsco, Inc.'s Q2 2025 performance, including record margins, tech-driven growth, and its strategic focus on overcoming market ...

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data that it believes can ...

Vinay Prasad, M.D., has left the FDA, less than three months into the role as director of the Center for Biologics Evaluation ...